Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
This case report demonstrates the effect of zoledronic acid (ZA) on a patient with bone metastatic hormone-refractory prostate cancer (HRPC) resistant to taxane, estramustine phosphate, carboplatin, and dexamethasone. The pathogenesis, diagnosis, and management of bone metastasis on HRPC are also reviewed.
Kikuno
Nobuyuki
N
Department of Urology, Shimane University School of Medicine, Izumo, Japan. k481219@med.shimane-u.ac.jp
Urakami
Shinji
S
Nakamura
Shigeru
S
Shiina
Hiroaki
H
Igawa
Mikio
M
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D043823:Taxoids / Q000627:therapeutic use; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D001952:Bridged-Ring Compounds; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; C080625:taxane; D004961:Estramustine; D000077211:Zoledronic Acid; D003907:Dexamethasone; D016190:Carboplatin